DRC & Research News

This page shares the latest news in T1D research and DRC’s community.

Get the most recent diabetes research news, delivered straight to your inbox

Diabetes Research

DRC Is Excited to Share This Breaking T1D News Announced Yesterday by the FDA

The FDA has just approved Provention Bio’s Tzield™ (teplizumab-mzwv) – the first drug therapy that can delay the onset of type-1 diabetes (T1D) for those at risk of developing the disease.  This is a huge milestone for T1D research and those in the T1D community. (Read the full FDA announcement HERE.)

The average delay in the onset of T1D observed in the clinical study of Tzield was approximately 3 years, with some study participants not yet acquiring type 1 diabetes at all.  “Today’s FDA decision gives people at risk of developing type 1 diabetes the gift of time,” said Aaron Kowalski, Ph.D., JDRF CEO. “For the first time ever, we have a way to change the course and slow the development of T1D.”  (Read JDRF’s full statement on the impact of this news to the T1D community HERE.)

Tzield is the result of decades of T1D research, which began with an early scientific study.  That study led to a JDRF grant to support a trial in patients.  The success of that trial study led to further studies and support from the National Institutes of Health (NIH), eventually leading to this exciting breakthrough that will impact the future of T1D treatment.

Scientific breakthroughs such as this one, often emerge due to the inventiveness of early-career scientists.  It is DRC’s mission to connect donors with early-career scientists, enabling them to perform peer-reviewed, novel research designed to prevent and cure type 1 diabetes, minimize its complications, and improve the quality of life for those living with the disease.

Thus far, 10+ of our funded studies by early-career scientists have secured follow-on funding to continue their studies which could lead to breakthroughs like the milestone announced today.

You could help fund the next T1D breakthrough!  DONATE HERE 

Learn More +
Connecting for a Cure DRC

November 2022 Newsletter

Let’s be honest. With the hectic pace of life, you might wonder why you should spend your precious time reading a newsletter, especially one about diabetes research. But have you ever paused to consider the impact this information can have on you or someone close to you? Let me explain why you should read the November 2022 Newsletter from the Diabetes Research Connection (DRC), a charitable organization dedicated to advancing diabetes research.

Understanding Diabetes Research Connection (DRC)

The DRC is not just a charity; it’s a bridge connecting innovative researchers, passionate donors, and individuals affected by diabetes. Its mission? To conquer the global challenge of diabetes through research.

Importance of Reading DRC’s November 2022 Newsletter

This particular newsletter from November 2022 is a treasure trove of information. Let’s take a closer look at what you might find.

Updates on Latest Research Findings

The field of diabetes research is fast-paced. The newsletter covers new developments, ensuring you stay informed about advancements that could transform lives.

Success Stories of Research Grant Beneficiaries

It’s not all facts and figures. The newsletter features real stories from researchers whose work has been made possible by DRC’s funding.

Opportunities for Community Engagement

Community engagement is at the heart of the DRC. Through the newsletter, you’ll discover opportunities to get involved and make a difference.

Deep Dive into the November 2022 Newsletter

This section delves deeper into what you can expect from the specific November 2022 edition.

Highlighted Research Studies 

Impact of Breakthrough Research 

The newsletter highlights cutting-edge studies with the potential to revolutionize the understanding and treatment of diabetes.

Testimonies from Diabetes Patients

Importance of Patients’ Voices

The personal stories from those living with diabetes provide a crucial perspective often missing in academic research.

Upcoming Events and Fundraisers

Why Your Participation Matters 

The newsletter promotes upcoming events and fundraisers, giving youthe chance to take part in the fight against diabetes.

The Value of Supporting DRC and Diabetes Research 

You might ask, “Why does this matter to me?” Well, let’s break it down.

The Role of Public Support in Advancing Research 

Public involvement is not just desirable—it’s necessary. The backing of the community propels research efforts, making breakthroughs possible.

How Donations Drive Impact

Your support, be it financial or through participation in events, fuels the very research that could improve, or even save, countless lives.


In conclusion, the DRC’s November 2022 Newsletter offers more than just an update—it’s a testament to the power of research, the strength of community, and the hope for a future free from diabetes. You’re not just reading a newsletter; you’re becoming a part of a mission that can change lives. Now, isn’t that a compelling reason to give it a read?


  1. What is the Diabetes Research Connection (DRC)?
    • The DRC is a nonprofit organization dedicated to funding research aimed at preventing, curing, and better managing diabetes.
  2. Why should I read DRC’s November 2022 Newsletter?
    • The newsletter offers insights into the latest research findings, success stories, and ways you can contribute to the fight against diabetes.
  3. What kind of research does DRC fund?
    • The DRC funds innovative, early-career scientists pursuing research in all forms of diabetes.
  4. How can I support DRC?
    • You can support DRC through donations, participation in fundraising events, or by spreading the word about their work.
  5. Where can I access DRC’s November 2022 Newsletter?
    • The newsletter is available on DRC’s official website, and you can also subscribe to receive future newsletters via email.

Please enjoy this month’s newsletter, featuring:

        • Researchers Impacting Our Mission
        • November’s Matching Gift Campaign
        • Meet Our New Executive Director
        • DRC’s Seaside Silent Auction
        • Thank You to Our Sponsors!



View the Newsletter here

Learn More +


See our approved research projects and campaigns.

Role of the integrated stress response in type 1 diabetes pathogenesis
In individuals with type 1 diabetes (T1D), the insulin-producing beta cells are spontaneously destroyed by their own immune system. The trigger that provokes the immune system to destroy the beta cells is unknown. However, accumulating evidence suggest that signals are perhaps first sent out by the stressed beta cells that eventually attracts the immune cells. Stressed cells adapt different stress mitigation systems as an adaptive response. However, when these adaptive responses go awry, it results in cell death. One of the stress response mechanisms, namely the integrated stress response (ISR) is activated under a variety of stressful stimuli to promote cell survival. However, when ISR is chronically activated, it can be damaging to the cells and can lead to cell death. The role of the ISR in the context of T1D is unknown. Therefore, in this DRC funded study, we propose to study the ISR in the beta cells to determine its role in propagating T1D.
Wearable Skin Fluorescence Imaging Patch for the Detection of Blood Glucose Level on an Engineered Skin Platform
A Potential Second Cure for T1D by Re-Educating the Patient’s Immune System
L Ferreira
Validating the Hypothesis to Cure T1D by Eliminating the Rejection of Cells From Another Person by Farming Beta Cells From a Patient’s Own Stem Cells
Han Zhu
Taming a Particularly Lethal Category of Cells May Reduce/Eliminate the Onset of T1D
JRDwyer 2022 Lab 1
Can the Inhibition of One Specific Body Gene Prevent Type 1 Diabetes?
Is Cholesterol Exacerbating T1D by Reducing the Functionality and Regeneration Ability of Residual Beta Cells?
Regeneration Ability of Residual Beta Cells
A Call to Question… Is T1D Caused by Dysfunctionality of Two Pancreatic Cells (β and α)?
Xin Tong
Novel therapy initiative with potential path to preventing T1D by targeting TWO components of T1D development (autoimmune response and beta-cell survival)
flavia pecanha